286 related articles for article (PubMed ID: 11697647)
1. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.
Laczika K; Mitterbauer G; Mitterbauer M; Knöbl P; Schwarzinger I; Greinix HT; Rabitsch W; Fonatsch C; Mannhalter C; Lechner K; Jaeger U
Leuk Lymphoma; 2001; 42(5):923-31. PubMed ID: 11697647
[TBL] [Abstract][Full Text] [Related]
2. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
[TBL] [Abstract][Full Text] [Related]
3. Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia: a single center study.
Mitterbauer M; Mitterbauer-Hohendanner G; Sperr WR; Kalhs P; Greinix HT; Fonatsch C; Haas OA; Jäger U; Mannhalter C; Lechner K
Leuk Lymphoma; 2004 May; 45(5):971-7. PubMed ID: 15291357
[TBL] [Abstract][Full Text] [Related]
4. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
[TBL] [Abstract][Full Text] [Related]
5. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study.
Laczika K; Novak M; Hilgarth B; Mitterbauer M; Mitterbauer G; Scheidel-Petrovic A; Scholten C; Thalhammer-Scherrer R; Brugger S; Keil F; Schwarzinger I; Haas OA; Lechner K; Jaeger U
J Clin Oncol; 1998 Apr; 16(4):1519-25. PubMed ID: 9552061
[TBL] [Abstract][Full Text] [Related]
6. Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely.
Martinelli G; Rondoni M; Buonamici S; Ottaviani E; Piccaluga PP; Malagola M; Baccarani M
Haematologica; 2004 Apr; 89(4):495-7. PubMed ID: 15075086
[TBL] [Abstract][Full Text] [Related]
7. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.
Marcucci G; Caligiuri MA; Döhner H; Archer KJ; Schlenk RF; Döhner K; Maghraby EA; Bloomfield CD
Leukemia; 2001 Jul; 15(7):1072-80. PubMed ID: 11455976
[TBL] [Abstract][Full Text] [Related]
8. Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFbeta/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely.
Martinelli G; Buonamici S; Visani G; Malagola M; Piccaluga PP; Isidori A; Bosi C; Bonifazi F; Soverini S; Terragna C; Amabile M; Giannini B; Baccarani M
Leukemia; 2003 Mar; 17(3):650-1; author reply 651-2. PubMed ID: 12646962
[No Abstract] [Full Text] [Related]
9. Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission.
Tobal K; Johnson PR; Saunders MJ; Harrison CJ; Liu Yin JA
Br J Haematol; 1995 Sep; 91(1):104-8. PubMed ID: 7577615
[TBL] [Abstract][Full Text] [Related]
10. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
[TBL] [Abstract][Full Text] [Related]
11. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state.
Buonamici S; Ottaviani E; Testoni N; Montefusco V; Visani G; Bonifazi F; Amabile M; Terragna C; Ruggeri D; Piccaluga PP; Isidori A; Malagola M; Baccarani M; Tura S; Martinelli G
Blood; 2002 Jan; 99(2):443-9. PubMed ID: 11781223
[TBL] [Abstract][Full Text] [Related]
12. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
Xiaosu Z; Leqing C; Yazhen Q; Yu W; Xiaohui Z; Lanping X; Xiaojun H; Yingjun C
Ann Hematol; 2019 Jan; 98(1):73-81. PubMed ID: 30159599
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
Perea G; Lasa A; Aventín A; Domingo A; Villamor N; Queipo de Llano MP; Llorente A; Juncà J; Palacios C; Fernández C; Gallart M; Font L; Tormo M; Florensa L; Bargay J; Martí JM; Vivancos P; Torres P; Berlanga JJ; Badell I; Brunet S; Sierra J; Nomdedéu JF;
Leukemia; 2006 Jan; 20(1):87-94. PubMed ID: 16281071
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.
Morschhauser F; Cayuela JM; Martini S; Baruchel A; Rousselot P; Socié G; Berthou P; Jouet JP; Straetmans N; Sigaux F; Fenaux P; Preudhomme C
J Clin Oncol; 2000 Feb; 18(4):788-94. PubMed ID: 10673520
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR.
Mitterbauer G; Zimmer C; Fonatsch C; Haas O; Thalhammer-Scherrer R; Schwarzinger I; Kalhs P; Jaeger U; Lechner K; Mannhalter C
Leukemia; 1999 Oct; 13(10):1519-24. PubMed ID: 10516752
[TBL] [Abstract][Full Text] [Related]
17. Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFbeta/MYH11 transcript.
Martinelli G; Ottaviani E; Testoni N; Montefusco V; Pastano R; Tura S
Haematologica; 2000 May; 85(5):552-5. PubMed ID: 10800179
[No Abstract] [Full Text] [Related]
18. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
Corbacioglu A; Scholl C; Schlenk RF; Eiwen K; Du J; Bullinger L; Fröhling S; Reimer P; Rummel M; Derigs HG; Nachbaur D; Krauter J; Ganser A; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(23):3724-9. PubMed ID: 20625124
[TBL] [Abstract][Full Text] [Related]
19. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion.
van der Reijden BA; Simons A; Luiten E; van der Poel SC; Hogenbirk PE; Tönnissen E; Valk PJ; Löwenberg B; De Greef GE; Breuning MH; Jansen JH
Br J Haematol; 2002 Aug; 118(2):411-8. PubMed ID: 12139724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
